Sigilon Therapeutics Company
Sigilon is a biotech company which specializes in creating immune privileged products for unmet clinical needs.
Technology:
Cell-based gene therapy, Stem cell therapy
Industry:
P4 Medicine, Public
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2015-01-01
Employees Number:
51-100
Funding Status:
IPO
Investors Number:
5
Total Funding:
263200000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2020-12-03
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership